Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody

ABSTRACT The identification and characterization of new human monoclonal antibodies (hMAbs) able to neutralize primary human immunodeficiency virus type 1 (HIV-1) isolates from different subtypes may help in our understanding of the mechanisms of virus entry and neutralization and in the development of entry inhibitors and vaccines. For enhanced selection of broadly cross-reactive antibodies, soluble HIV-1 envelope glycoproteins (Envs proteins) from two isolates complexed with two-domain soluble CD4 (sCD4) were alternated during panning of a phage-displayed human antibody library; these two Env proteins (89.6 and IIIB gp140s), and one additional Env (JR-FL gp120) alone and complexed with sCD4 were used for screening. An antibody with relatively long HCDR3 (17 residues), designated m14, was identified that bound to all antigens and neutralized heterologous HIV-1 isolates in multiple assay formats. Fab m14 potently neutralized selected well-characterized subtype B isolates, including JRCSF, 89.6, IIIB, and Yu2. Immunoglobulin G1 (IgG1) m14 was more potent than Fab m14 and neutralized 7 of 10 other clade B isolates; notably, although the potency was on average significantly lower than that of IgG1 b12, IgG1 m14 neutralized two of the isolates with significantly lower 50% inhibitory concentrations than did IgG1 b12. IgG1 m14 neutralized four of four selected clade C isolates with potency higher than that of IgG1 b12. It also neutralized 7 of 17 clade C isolates from southern Africa that were difficult to neutralize with other hMAbs and sCD4. IgG1 m14 neutralized four of seven primary HIV-1 isolates from other clades (A, D, E, and F) much more efficiently than did IgG1 b12; for the other three isolates, IgG b12 was much more potent. Fab m14 bound with high (nanomolar range) affinity to gp120 and gp140 from various isolates; its binding was reduced by soluble CD4 and antibodies recognizing the CD4 binding site (CD4bs) on gp120, and its footprint as defined by alanine-scanning mutagenesis overlaps that of b12. These results suggest that m14 is a novel CD4bs cross-reactive HIV-1-neutralizing antibody that exhibits a different inhibitory profile compared to the only known potent broadly neutralizing CD4bs human antibody, b12, and may have implications for our understanding of the mechanisms of immune evasion and for the development of inhibitors and vaccines.

[1]  H. Katinger,et al.  Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. , 2003, The Journal of antimicrobial chemotherapy.

[2]  S. Rybak,et al.  Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. , 2003, Journal of immunological methods.

[3]  S. Zolla-Pazner,et al.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies , 1994, Journal of virology.

[4]  H. McClure,et al.  Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. , 2002, Vaccine.

[5]  Jamie K. Scott,et al.  Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[6]  H. Katinger,et al.  Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation , 2002, AIDS.

[7]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[8]  G. Quinnan,,et al.  Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes , 1998, Journal of Virology.

[9]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[10]  C. Barbas,et al.  Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. , 1996, AIDS research and human retroviruses.

[11]  J. Sodroski,et al.  Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. , 1998, AIDS research and human retroviruses.

[12]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[13]  H. McClure,et al.  Antibody protection: passive immunization of neonates against oral AIDS virus challenge. , 2003, Vaccine.

[14]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[15]  D. Burton,et al.  The antibody response in HIV-1 infection. , 1997, AIDS.

[16]  T. Hideshima,et al.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. , 1991, Journal of immunology.

[17]  D. Dimitrov,et al.  Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. , 2004, Journal of molecular biology.

[18]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[19]  H. Alter,et al.  Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. , 1999, AIDS research and human retroviruses.

[20]  L. Mollet,et al.  A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV , 2004, Journal of Virology.

[21]  J. Margolick,et al.  Primary Virus Envelope Cross-Reactivity of the Broadening Neutralizing Antibody Response during Early Chronic Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[22]  S. Zolla-Pazner,et al.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.

[23]  Paul W. H. I. Parren,et al.  Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[24]  J. McKeating,et al.  Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. , 2002, The Journal of general virology.

[25]  A. Trkola,et al.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. , 2000, The Journal of infectious diseases.

[26]  E. Coligan.  Current protocols in immunology , 1991 .

[27]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[28]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[29]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[30]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[31]  John P. Moore,et al.  Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542 , 2004, Antimicrobial Agents and Chemotherapy.

[32]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[33]  G R Pilkington,et al.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. , 1993, Journal of molecular biology.

[34]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[35]  S. Zolla-Pazner,et al.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.

[36]  S. Hammer,et al.  Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. , 1998, AIDS research and human retroviruses.

[37]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[38]  C. Broder,et al.  UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .

[39]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[40]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[41]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[42]  N. Haigwood,et al.  Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. , 2004, Journal of acquired immune deficiency syndromes.

[43]  Igor A. Sidorov,et al.  Concordant Modulation of Neutralization Resistance and High Infectivity of the Primary Human Immunodeficiency Virus Type 1 MN Strain and Definition of a Potential gp41 Binding Site in gp120 , 2003, Journal of Virology.

[44]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[45]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[46]  G. Quinnan,,et al.  Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains , 1999, Journal of Virology.

[47]  C. Barbas,et al.  Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.

[48]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[49]  R. M. Hendry,et al.  Neutralization of primary HIV‐1 isolates by anti‐envelope monoclonal antibodies , 1995, AIDS.

[50]  T. Hope,et al.  Association of Chemokine-mediated Block to HIV Entry with Coreceptor Internalization* , 2002, The Journal of Biological Chemistry.

[51]  H. Katinger,et al.  Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.

[52]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[53]  D. Burton.  A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  C. Broder,et al.  Induction of Primary Virus-Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Antibodies in Small Animals by Using an Alphavirus-Derived In Vivo Expression System , 2003, Journal of Virology.

[55]  Susan Zolla-Pazner,et al.  A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.

[56]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[57]  C. Barbas,et al.  Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. , 1997, Journal of molecular biology.

[58]  R. Ruprecht,et al.  Neutralizing antibodies against HIV -- back in the major leagues? , 2002, Current opinion in immunology.

[59]  M. Cho,et al.  Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. , 2003, Virology.

[60]  H. Katinger,et al.  A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 , 2002, AIDS.

[61]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[62]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[63]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[64]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[65]  D. Dimitrov,et al.  Multiple Interactions across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[66]  H. Katinger,et al.  The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate , 1996, Journal of virology.

[67]  Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades. , 2004, Antiviral research.

[68]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[69]  M. Hilgartner,et al.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. , 1991, Research in virology.

[70]  D R Burton,et al.  In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope , 1996, Journal of virology.

[71]  D. Montefiori,et al.  Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa , 2002, Journal of Virology.

[72]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[73]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[74]  Susan Zolla-Pazner,et al.  A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.

[75]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[76]  T. Ndung’u,et al.  Construction and Analysis of an Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone , 2001, Journal of Virology.